View Older Stories View More Recent Stories
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
-
TD Cowen on Hims and Hers (HIMS): 'acquisition of ZAVA reflects its commitment to expand into international markets'
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.1 calls to 1 put with a focus on June 60, 65 and 70 calls as share price up 4.7%
-
Hims & Hers Health, Inc. (HIMS) Rapidly Selling $6 to a 60 Handle, Remains +675bps on Day
-
Truist on Hims and Hers (HIMS): 'likely has the opportunity to up-sell', 'we believe HIMS is likely to still have financial capacity to announce additional deals'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30
-
Leerink Partners on Hims and Hers (HIMS): 'we do see some execution and integration risk associated with the deal'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), 'Core growth in US slowing notably'
-
Hims & Hers Health, Inc. (HIMS) to Acquire ZAVA
-
Hims & Hers Health, Inc. (HIMS) To Acquire European Telehealth Platform Zava - CNBC
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.2 calls to 1 put with a focus on June 6 weekly calls as share price up 2.3%
-
Hims and Hers (HIMS) to cut over 4% of staff amid strategy shift - Bloomberg
-
Hims & Hers Health, Inc. (HIMS) Introduces 6-Month Wegovy New Customer Offer
-
Citi Drops Third Note on Hims and Hers (HIMS) Inside 20 Hours: 'HIMS is now offering discounts on its bundles, effectively passing through the price discount'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), Comments on Novo's Wegovy Price Promo: 'We see this as another potential headwind for HIMS
-
Hims & Hers Health: Analysts remain bearish
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
BofA Securities Negative on Hims and Hers (HIMS): 'Observed total sales and GLP-1 sales decline in April'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30, 'we do think that this will be a slight headwind to HIMS'
-
Truist: 'we share some interesting takeaways from the ruling that could provide a read through on the Wegovy/Ozempic case'
-
Hims and Hers (HIMS) PT Raised to $45 at Truist, 'unless the company's Q2 revenues exceed its current guidance, the ramp reflected in HIMS' 2H outlook might be a stretch'
-
Hims & Hers Health, Inc. (HIMS) Announces Proposed Convertible Senior Notes Offering
-
Hims & Hers Health, Inc. (HIMS) Appoints Mo Elshenawy as CTO
-
Hims and Hers (HIMS) PT Raised at Piper Sandler; 'Another Beat, but Show-Me Story Builds'
-
Hims and Hers (HIMS) PT Raised to $28 at BofA Securities
-
Hims and Hers (HIMS) PT Raised to $38 at TD Cowen
-
Hims and Hers (HIMS) PT Raised to $42 at Leerink Partners
-
Needham on Hims and Hers (HIMS): '2Q Transition Should Not Distract From HIMS Long-Term Trajectory'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS)
-
Leerink Partners Reiterates Market Perform Rating on Hims and Hers (HIMS)
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
Morgan Stanley on Hims and Hers (HIMS): 'This marked the first time in the company’s history that next quarter revenue was guided below the Street'
-
Hims & Hers Health, Inc. (HIMS) Misses Q1 EPS by 3c; Issues Mixed Outlook
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to1 put into quarter results
-
Hims & Hers is due to report after the bell on Monday. Here's what to expect
-
Hims and Hers (HIMS) New COO 'Logical Hire' - Leerink Partners
-
BofA on Hims and Hers (HIMS), PT $26: 'maintain our Underperform rating given weakening consumer trends and growth rates exiting March'
-
Hims & Hers Health, Inc. (HIMS) Appoints Nader Kabbani as COO
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.6 calls to 1 put into quarter results and outlook
-
Hims & Hers Health, Inc. (HIMS) May 9 weekly 36.50 straddle priced into quarter results
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.8 calls to 1 put on 406K contracts as share price up 24%
-
Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $35, 'Still Struggle to Be Constructive'
-
TD Cowen (which downgraded HIMS yday) Comments on Hims and Hers (HIMS): 'The partnership came as a surprise to us'
-
Hims and Hers (HIMS) PT Raised to $26 at BofA Securities 'and increasing our target EBITDA multiple from 17x to 20- 21x to reflect a longer runway of GLP-1 sales'
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS), PT $40
-
Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), 'We think HIMS will not make any margin on dispensing of Wegovy'
-
Hims & Hers Health, Inc. (HIMS) Short Sellers Pressured as Shares Spike Following Novo Nordisk (NVO) Pact
-
Hims & Hers Health, Inc. (HIMS) and Novo Nordisk Team Up to Expand Affordable Access to Care
